/ Cadila Healthcare Limited Clarifies It Received 'Untitled Letter' From USFDA Stocks Up 2.3% ~ Ways2Capital|Stock Tips|Stock Market Tips|Intraday Stock Tips|Stock Trading Tips|NSE BSE Tips

Wednesday, 28 December 2016

Cadila Healthcare Limited has written to the BSE and NSE, clarifying that  Zydus Discovery DMCC, a 100% subsidiary of Cadila Healthcare Ltd has received an "Untitled Letter" and not a "Warning Letter" from the USFDA. The letter is related to a product promotion of a drug which is not marketed in the US and is currently marketed only in India. The company said it has taken necessary action to respond to the letter. 

Cadila Healthcare Ltd is currently trading at Rs 358, up by Rs 8.25 or 2.36% from its previous closing of Rs 349.75 on the BSE. The scrip opened at Rs 350.2 and has touched a high and low of Rs 358.7 and Rs 343.5 respectively. So far 475312(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs 35805.4 crore.

The BSE group 'A' stock of face value Rs 1 has touched a 52 week high of Rs 429.45 on 01-Nov-2016 and a 52 week low of Rs 295.5 on 18-Jan-2016. Last one week high and low of the scrip stood at Rs 373.45 and Rs 329.95 respectively.

The promoters holding in the company stood at 74.79 % while Institutions and Non-Institutions held 17.25 % and 7.96 % respectively. The stock is currently trading below its 50 DMA.
or Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007
Give a Missed Call for Free Trial - 09699997717